Skip to main content
Clinical Trials/JPRN-jRCT1031220275
JPRN-jRCT1031220275
Recruiting
未知

A prospective observational study on the efficacy and safety of the Gefapixant in patients with interstitial lung disease

Abe Mitsuhiro0 sites30 target enrollmentAugust 17, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
interstitial lung disease
Sponsor
Abe Mitsuhiro
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 17, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Abe Mitsuhiro

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with interstitial lung disease
  • Patients who have been fully informed of the study and given the consent
  • More than 18 years old patients

Exclusion Criteria

  • Patients unable to give the consent
  • Patients allergic to sulfonamide group
  • Other patients deemed unsuitable for the study by the principal investigator or the sub\-investigator
  • Patients already taking gefapixant

Outcomes

Primary Outcomes

Not specified

Similar Trials